Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: diablo who wrote (215)	1/15/1998 9:13:00 PM
From: JMarcus	Read Replies (1) of 1494

NTIIC continues to be a topic of discussion on the Neurex thread. Dr. John M. de Castro responds to NeuroInvestment: Message 3180988 > 2) If you want something genuine to worry about, look for the release of the neuropathic pain Phase II data from the Neurobiological Technologies memantine trial, due out late Jan/early Feb. While I expect memantine to have less magnitude of effect, it is given orally and thus is a lot cheaper and easier to utilize. If successful, NTI would push a Phase III partnership ASAP, since they are near bankrupt.It could be a competitor for the mild-moderate range of neuropathic pain patients. Now here I agree with you. NTII is in a great position because they are addressing the really huge neuropathic pain market. NXCO is only addressing a relatively small niche market. The reason to suspect that memantine will be less potent is because it is a noncompetitive NMDA antagonist. This is actually good. It maybe slightly less potent. But, it has a proven record of safety with humans for over 15 years. I own NTIIC stock and do not own NXCO. So take my self serving comments for what they are worth. John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next